MA52488A - Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation - Google Patents

Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation

Info

Publication number
MA52488A
MA52488A MA052488A MA52488A MA52488A MA 52488 A MA52488 A MA 52488A MA 052488 A MA052488 A MA 052488A MA 52488 A MA52488 A MA 52488A MA 52488 A MA52488 A MA 52488A
Authority
MA
Morocco
Prior art keywords
manufacturing
inhibitor compounds
use procedures
rip1 inhibitor
rip1
Prior art date
Application number
MA052488A
Other languages
English (en)
Other versions
MA52488B1 (fr
Inventor
Somasekhar Bhamidipati
Esteban Masuda
Simon Shaw
Vanessa Taylor
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of MA52488A publication Critical patent/MA52488A/fr
Publication of MA52488B1 publication Critical patent/MA52488B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MA52488A 2018-05-03 2019-05-02 Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation MA52488B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862666462P 2018-05-03 2018-05-03
PCT/US2019/030476 WO2019213447A1 (fr) 2018-05-03 2019-05-02 Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation

Publications (2)

Publication Number Publication Date
MA52488A true MA52488A (fr) 2021-03-10
MA52488B1 MA52488B1 (fr) 2023-11-30

Family

ID=66530556

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52488A MA52488B1 (fr) 2018-05-03 2019-05-02 Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation

Country Status (38)

Country Link
US (8) US10815206B2 (fr)
EP (2) EP4248975A3 (fr)
JP (4) JP2021523226A (fr)
KR (1) KR102808215B1 (fr)
CN (4) CN120535514A (fr)
AU (2) AU2019262144B2 (fr)
BR (1) BR112020022420A2 (fr)
CA (1) CA3099037A1 (fr)
CL (1) CL2020002841A1 (fr)
CO (1) CO2020015156A2 (fr)
CR (1) CR20200581A (fr)
DK (1) DK3788044T3 (fr)
DO (2) DOP2020000198A (fr)
EA (1) EA202092580A1 (fr)
EC (1) ECSP20078326A (fr)
ES (1) ES2956087T3 (fr)
FI (1) FI3788044T3 (fr)
HR (1) HRP20231381T1 (fr)
HU (1) HUE063896T2 (fr)
IL (2) IL278417B2 (fr)
JO (2) JOP20200278B1 (fr)
LT (1) LT3788044T (fr)
MA (1) MA52488B1 (fr)
MD (1) MD3788044T2 (fr)
MX (1) MX2020011621A (fr)
MY (1) MY208132A (fr)
PE (1) PE20211383A1 (fr)
PH (1) PH12020551847A1 (fr)
PL (1) PL3788044T3 (fr)
PT (1) PT3788044T (fr)
RS (1) RS64736B1 (fr)
SA (1) SA520420468B1 (fr)
SG (1) SG11202010915XA (fr)
SI (1) SI3788044T1 (fr)
SM (1) SMT202300313T1 (fr)
UA (1) UA128369C2 (fr)
WO (1) WO2019213447A1 (fr)
ZA (2) ZA202007486B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL278416B2 (en) 2018-05-03 2023-12-01 Rigel Pharmaceuticals Inc RIP1 inhibitory compounds and methods for their preparation and use
PE20211383A1 (es) 2018-05-03 2021-07-27 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos
CN111138448B (zh) * 2018-11-02 2022-08-02 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
WO2020088194A1 (fr) * 2018-11-02 2020-05-07 中国科学院上海药物研究所 Amide hétérocyclique inhibant la kinase rip1 et ses applications
US12365695B2 (en) * 2019-08-09 2025-07-22 Bisichem Co., Ltd. Fused ring heteroaryl compounds as RIPK1 inhibitors
PE20221628A1 (es) * 2019-09-06 2022-10-19 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
WO2021046515A1 (fr) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibiteurs de la protéine kinase i interagissant avec le récepteur pour le traitement d'une maladie
MX2022002717A (es) 2019-09-06 2022-08-10 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos.
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
WO2021080757A1 (fr) 2019-10-21 2021-04-29 Google Llc Consentement vérifiable permettant la protection de la vie privée
HRP20251589T1 (hr) 2019-11-07 2026-01-30 Rigel Pharmaceuticals, Inc. Heterociklični spojevi koji inhibiraju rip1
BR112022010082A2 (pt) * 2019-11-26 2022-08-30 Univ Texas Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
CN115515940A (zh) * 2020-02-28 2022-12-23 德州大学系统董事会 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
AR122703A1 (es) 2020-07-01 2022-09-28 Rigel Pharmaceuticals Inc Inhibidores de rip1k
WO2022171111A1 (fr) * 2021-02-10 2022-08-18 Zai Lab (Us) Llc Composé bicyclique fusionné hétéroaryle utile en tant qu'inhibiteur de la rip1-kinase et ses utilisations
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
CN114989156B (zh) * 2021-05-19 2024-07-05 成都贝诺科成生物科技有限公司 一种受体相互作用蛋白抑制剂及其制备方法和用途
KR20240135076A (ko) 2021-08-10 2024-09-10 애브비 인코포레이티드 니코틴아미드 ripk1 억제제
CA3240557A1 (fr) * 2021-12-16 2023-06-22 Shaoming DUAN Formes cristallines d'un inhibiteur de ripk1
WO2023138317A1 (fr) * 2022-01-21 2023-07-27 中国科学院上海药物研究所 Composé ayant une activité inhibitrice de ripk1, son procédé de préparation et son utilisation
EP4495119A4 (fr) * 2022-03-16 2025-06-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Composé hétérocyclique fusionné, son procédé de préparation et son utilisation médicale
CN114736197B (zh) * 2022-06-13 2022-09-13 南京医工医药技术有限公司 咪唑啉酮衍生物及其用途
CN115353513A (zh) * 2022-07-29 2022-11-18 中国人民解放军海军军医大学 一种抑制程序性细胞坏死的硫代七元环衍生物及其应用
AU2024309577A1 (en) 2023-06-26 2026-01-15 Eli Lilly And Company Dosage regimens for the treatment of autoimmune and inflammatory diseases using ly3871801

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DK0431519T3 (da) 1989-12-04 1994-07-04 Searle & Co System til transdermal indgivelse af albuterol
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 多重層型バリアー構造体
EP0553769B1 (fr) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Raquette, en particulier raquette de tennis
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
CA2696349A1 (fr) 2007-08-15 2009-02-19 President And Fellows Of Harvard College Inhibiteurs heterocycliques de la necroptose
TWI648273B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
AU2015304851A1 (en) * 2014-08-21 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as RIP1 kinase inhibitors as medicaments
RU2017131862A (ru) 2015-02-13 2019-03-13 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед КРИСТАЛЛИЧЕСКИЕ ФОРМЫ (S)-5-БЕНЗИЛ-N-(5-МЕТИЛ-4-ОКСО-2,3,4,5-ТЕТРАГИДРОБЕНЗО[b][1,4]ОКСАЗЕПИН-3-ИЛ)-4H-1,2,4-ТРИАЗОЛ-3-КАРБОКСАМИДА
CA3094197C (fr) 2015-07-02 2023-02-28 F. Hoffmann-La Roche Ag Lactames bicycliques et leurs methodes d'utilisation
DK3362449T3 (da) 2015-10-13 2021-07-19 Inst Nat Sante Rech Med Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose
CN108431004B (zh) 2015-10-23 2021-02-12 武田药品工业株式会社 杂环化合物
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
IL287136B2 (en) * 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
JP7349359B2 (ja) * 2016-10-17 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
IL278416B2 (en) * 2018-05-03 2023-12-01 Rigel Pharmaceuticals Inc RIP1 inhibitory compounds and methods for their preparation and use
PE20211383A1 (es) * 2018-05-03 2021-07-27 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos
TW202019913A (zh) 2018-06-26 2020-06-01 中國科學院上海有機化學研究所 細胞壞死抑制劑及其製備方法和用途
CN111138448B (zh) 2018-11-02 2022-08-02 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
WO2020088194A1 (fr) 2018-11-02 2020-05-07 中国科学院上海药物研究所 Amide hétérocyclique inhibant la kinase rip1 et ses applications
PE20221628A1 (es) 2019-09-06 2022-10-19 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k

Also Published As

Publication number Publication date
AU2023254980A1 (en) 2023-11-16
DOP2020000198A (es) 2021-04-30
CN120535513A (zh) 2025-08-26
HRP20231381T1 (hr) 2024-03-01
EP3788044A1 (fr) 2021-03-10
SI3788044T1 (sl) 2023-12-29
JP7187729B2 (ja) 2022-12-12
JP2022160665A (ja) 2022-10-19
JOP20200278A1 (ar) 2020-11-03
KR20210005222A (ko) 2021-01-13
US20200407332A1 (en) 2020-12-31
IL278417B2 (en) 2024-05-01
US11332451B2 (en) 2022-05-17
US10815206B2 (en) 2020-10-27
US20230113841A1 (en) 2023-04-13
JOP20200278B1 (ar) 2024-04-18
JP2021523226A (ja) 2021-09-02
IL299784A (en) 2023-03-01
AU2023254980B2 (en) 2025-09-18
MD3788044T2 (ro) 2023-12-31
MY208132A (en) 2025-04-17
NZ770295A (en) 2025-05-30
CL2020002841A1 (es) 2021-05-24
ES2956087T3 (es) 2023-12-13
FI3788044T3 (fi) 2023-09-25
RS64736B1 (sr) 2023-11-30
CR20200581A (es) 2021-05-11
IL278417A (fr) 2020-12-31
UA128369C2 (uk) 2024-06-26
IL299784B1 (en) 2023-12-01
PE20211383A1 (es) 2021-07-27
BR112020022420A2 (pt) 2021-03-02
US20210040053A1 (en) 2021-02-11
ZA202007486B (en) 2022-06-29
CO2020015156A2 (es) 2021-02-26
IL278417B1 (en) 2024-01-01
EP3788044B1 (fr) 2023-08-09
CN112368278A (zh) 2021-02-12
JP2023022225A (ja) 2023-02-14
US20210238153A2 (en) 2021-08-05
MA52488B1 (fr) 2023-11-30
ECSP20078326A (es) 2021-03-31
DOP2023000169A (es) 2023-10-15
CN112368278B (zh) 2025-06-17
US20190337907A1 (en) 2019-11-07
PT3788044T (pt) 2023-08-31
US20210002237A1 (en) 2021-01-07
US11472782B2 (en) 2022-10-18
US20210002236A1 (en) 2021-01-07
HUE063896T2 (hu) 2024-02-28
KR102808215B1 (ko) 2025-05-19
JP7367169B2 (ja) 2023-10-23
WO2019213447A1 (fr) 2019-11-07
DK3788044T3 (da) 2023-10-02
IL299784B2 (en) 2024-04-01
JP2024009916A (ja) 2024-01-23
CA3099037A1 (fr) 2019-11-07
EA202092580A1 (ru) 2021-04-07
JOP20230272A1 (ar) 2023-10-26
SMT202300313T1 (it) 2024-01-10
ZA202108603B (en) 2022-03-30
SA520420468B1 (ar) 2024-04-28
PL3788044T3 (pl) 2024-02-12
PH12020551847A1 (en) 2021-06-28
US20210009537A1 (en) 2021-01-14
AU2019262144B2 (en) 2023-11-16
US12116354B2 (en) 2024-10-15
MX2020011621A (es) 2021-02-22
US20250034100A1 (en) 2025-01-30
JP7735368B2 (ja) 2025-09-08
EP4248975A3 (fr) 2024-03-13
EP4248975A2 (fr) 2023-09-27
US11370765B2 (en) 2022-06-28
CN120535512A (zh) 2025-08-26
US11370764B2 (en) 2022-06-28
US11377428B2 (en) 2022-07-05
SG11202010915XA (en) 2020-12-30
CN120535514A (zh) 2025-08-26
AU2019262144A1 (en) 2020-11-26
LT3788044T (lt) 2023-11-10

Similar Documents

Publication Publication Date Title
MA52488A (fr) Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation
MA52492A (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
EP4037695A4 (fr) Compositions oligonucléotidiques et leurs procédés d'utilisation
EP3775203A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3958872A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3429635A4 (fr) Composés anti-crispr et leurs procédés d'utilisation
MA42055A (fr) Composés antimicrobiens et procédés de fabrication et d'utilisation de ceux-ci
EP3641774A4 (fr) Composition gélifiée à base de pectine et leurs procédés de fabrication et d'utilisation
EP3720386A4 (fr) Constructions cutanées multicouches et leurs procédés de fabrication et d'utilisation
EP3368538A4 (fr) Inhibiteurs de la kinase wee 1 et leurs procédés de fabrication et d'utilisation
EP3768267A4 (fr) Composés inhibiteurs de kinase, compositions et procédés d'utilisation
MA49560A (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
MA50912A (fr) Inhibiteurs d'acss2 et leurs procédés d'utilisation
EP3886854A4 (fr) Composés pyrrole et pyrazole et leurs procédés d'utilisation
EP3468555A4 (fr) Composés antimicrobiens et leurs procédés d'utilisation
EP3717531A4 (fr) Revêtements résistant aux salissures biologiques et leurs procédés de fabrication et d'utilisation
EP3510023A4 (fr) Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procédés de fabrication
EP3836971A4 (fr) Conjugués et leurs procédés d'utilisation
EP3790552A4 (fr) Compositions de combinaison comprenant des composés de bisfluoroalkyle-1,4-benzodiazépinone et leurs procédés d'utilisation
EP3755723A4 (fr) Anticorps tgf-beta 1 anti-latents inter-espèces et leurs procédés d'utilisation
EP3965776A4 (fr) Compositions oligosaccharidiques et leurs procédés d'utilisation
EP3676294A4 (fr) Anticorps anti-cd et leurs procédés de fabrication et d'utilisation
EP3504546A4 (fr) Compositions de marqueurs et leurs procédés de fabrication et d'utilisation
EP3972646A4 (fr) Complexes d'apohémoglobine-haptoglobine et leurs procédés d'utilisation
EP3700519A4 (fr) Compositions de cannabinoïdes et leurs procédés d'utilisation